STOCK TITAN
  1. Home
  2. News
  3. LQDA

Liquidia to Participate in the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MORRISVILLE, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.

A webcast of the event will be available on the investors section of Liquidia’s website at https://liquidia.com/investors/events-and-presentations, and will be archived for 30 days following the event.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com


Stock LQDA logo
Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

#2414 Ranked by Market Cap
#717 Ranked by Stock Gains
N/A Ranked by Dividends

LQDA Latest News

Apr 2, 2024
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
Apr 1, 2024
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Mar 13, 2024
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Mar 6, 2024
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
Jan 30, 2024
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress

LQDA Stock Data

1.01B
49.94M
12.42%
51.22%
9.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MORRISVILLE

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.